Mechanisms of Molecular Glue Degraders and Their Applications in Hematological Malignancies

Abstract

Molecular glue degraders (MGDs) belong to a category of small-molecule compounds that bring E3 ubiquitin ligases and target proteins close to each other, thereby initiating the ubiquitination process and the subsequent breakdown of the target proteins. In the past few years, these substances have shown considerable therapeutic potential in the treatment of hematological malignancies. This review comprehensively summarizes the action mechanisms of MGDs, sorts out their preclinical and clinical advances in hematological cancers, and explores the existing challenges as well as future development directions. MGDs offer a new approach for cancer treatment, yet further research is needed to clarify their resistance mechanisms and improve the precision of target selection.